Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.83−11.27 (-79.93%)
Close on Nov 17, 2026Market cap $20.56MP/E –Yield –
Cue Biopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cue Biopharma's revenue for the twelve months ending Jun 30, 2026 was $37.65M, up 354.4% year over year. For fiscal 2025 it was $27.47M, up 195.7% from the year before. The highest annual figure on record is $27.47M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.47M | +195.7% |
| FY2024 | Dec 31, 2024 | $9.29M | +69.2% |
| FY2023 | Dec 31, 2023 | $5.49M | +341.0% |
| FY2022 | Dec 31, 2022 | $1.25M | -91.7% |
| FY2021 | Dec 31, 2021 | $14.94M | +373.7% |
| FY2020 | Dec 31, 2020 | $3.15M | -8.8% |
| FY2019 | Dec 31, 2019 | $3.46M | +202.7% |
| FY2018 | Dec 31, 2018 | $1.14M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.88M | +166.7% |
| Q1 FY2026 | Mar 31, 2026 | $5.69M | +1250.6% |
| Q4 FY2025 | Dec 31, 2025 | $21.94M | +1292.3% |
| Q3 FY2025 | Sep 30, 2025 | $2.15M | -35.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.95M | +11.1% |
| Q1 FY2025 | Mar 31, 2025 | $421.00K | -75.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.58M | -13.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.34M | +58.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.66M | +92.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.72M | +818.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.82M | +1106.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.10M | +2988.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.38M | +5215.4% |
| Q1 FY2023 | Mar 31, 2023 | $187.00K | -81.3% |
| Q4 FY2022 | Dec 31, 2022 | $151.00K | -98.2% |
| Q3 FY2022 | Sep 30, 2022 | $68.00K | -97.2% |
| Q2 FY2022 | Jun 30, 2022 | $26.00K | -99.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.00M | -35.6% |
| Q4 FY2021 | Dec 31, 2021 | $8.25M | +1636.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.40M | +240.2% |
| Q2 FY2021 | Jun 30, 2021 | $2.74M | +154.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.55M | +72.6% |
| Q4 FY2020 | Dec 31, 2020 | $475.33K | -54.7% |
| Q3 FY2020 | Sep 30, 2020 | $704.00K | -28.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.08M | +1.9% |
| Q1 FY2020 | Mar 31, 2020 | $900.00K | +143.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.05M | +217.4% |
| Q3 FY2019 | Sep 30, 2019 | $984.00K | +119.2% |
| Q2 FY2019 | Jun 30, 2019 | $1.06M | +513.4% |
| Q1 FY2019 | Mar 31, 2019 | $370.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $330.60K | – |
| Q3 FY2018 | Sep 30, 2018 | $449.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $172.00K | – |
See a number that looks wrong?